Atherosclerotic lesions in humans--plaque stabilization and regression.
Although lowering of total- and LDL-cholesterol with different methods, like dietary restrictions mostly combined with lipid-lowering drugs (monotherapy or combined drug therapy) or changes in lifestyle (e.g., cessation from smoking) have demonstrated significant clinical benefits in a number of clinical trials, the magnitude of angiographically proven regression of atherosclerotic lesions is relatively small despite aggressive lipid-lowering regimens. A potentially important therapeutic target especially for limited indications includes the use of LDL-apheresis, where functional and later morphological regression occurs.
D001161:Arteriosclerosis / Q000097:blood / Q000473:pathology* / Q000628:therapy; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000097:blood / Q000473:pathology / Q000628:therapy; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D002784:Cholesterol